[Featured Stock] GenCurix Rises on COVID-19 Diagnostic Kit Export Approval from MFDS
[Asia Economy Reporter Minwoo Lee] The stock price of GenCurix is on the rise. This appears to be due to receiving export approval for its COVID-19 diagnostic kit from the Ministry of Food and Drug Safety.
As of 2:06 PM on the 18th, GenCurix's stock price recorded 17,000 KRW, up 4.94% from the previous day. Around 1:51 PM, it even rose to 19,100 KRW, an increase of 17.90% compared to the previous closing price. The news of export approval for the COVID-19 diagnostic kit product from the Ministry of Food and Drug Safety seems to have acted as a positive factor.
On the 14th, the Ministry of Food and Drug Safety granted export approval for GenCurix's high-risk infectious disease immunoassay reagent 'JinPro COVID-19 IgG/IgM Test' under 'CVR001'. This product is an in vitro diagnostic medical device that qualitatively detects IgM and IgG antibodies against 'SARS-CoV-2' present in human serum, plasma, and whole blood using immunochromatography assay (ICA).
Hot Picks Today
"Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- Thai Freight Train Hits Bus: Engineer Tested Positive for Drugs and Lacked License
- "Striking Will Lead to Regret": Hyundai-Kia Employees Speak Out... Uneasy Stares Toward Samsung Union
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Meanwhile, GenCurix had previously obtained the European in vitro diagnostic reagent certification (CE-IVD) for two types of 'JinPro COVID-19 diagnostic kits' in March. In June, it also received emergency use authorization from the U.S. Food and Drug Administration (FDA).
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
